US Patent 12134777 Alphavirus replicon vector and immunotherapy by administering same
Patent 12134777 was granted and assigned to VLP Therapeutics on November, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 6 Nov, 2024
Golden AI
Edits made to:
Infobox (+46 properties)
Article (+292 characters)
US Patent 12134777 Alphavirus replicon vector and immunotherapy by administering same
Article
Patent abstract
Provided herein is a novel immunologically-active alphavirus replicon vector which comprises a nucleic acid encoding alphavirus nonstructural proteins nsp1-4 and a cytokine protein(s)/polypeptide(s), which is useful for the treatment of a cancer and/or an inflammatory disease.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Jonathan F. Smith0
Wataru Akahata0
Date of Patent
November 5, 2024
0Patent Application Number
172429160
Date Filed
April 28, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 12134777 Alphavirus replicon vector and immunotherapy by administering same
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.